News Articles February 2022
Written on 04 February 2022.
Pituitary Facts And Resources




News Articles April 2026
Pituitary story: 10-year-old pituitary patient honored for bravery

A ten-year-old Scottish girl has been honored for her bravery as she underwent surgery for a pituitary tumor. Read more: https://www.northern-times.co.uk/news/she-s-an-absolute-star-inverness-pupil-honoured-for-brave-431104/
Teen overcomes Cushing’s Disease
A 17-year-old girl in North Carolina is doing well after surgery to remove a pituitary tumor caused by Cushing’s Disease. She is an avid runner who suffered headaches and fatigue before her diagnosis. Read more: https://www.wect.com/2026/04/01/believe-them-teen-runner-diagnosed-with-rare-cushings-disease-after-years-symptoms/
Pituitary story: Cushing’s at age 27
A 27-year-old woman experienced a lack of menses and unexplained weight gain before being diagnosed with Cushing’s disease. She had surgery at Cleveland Clinic in Florida and has returned to a normal life. Read more: https://my.clevelandclinic.org/patient-stories/960-in-her-twenties-yoselin-needed-pituitary-tumor-surgery
Mobile MRI during pituitary surgery
An article on MSN.com looks at the use of mobile brain scanners during pituitary surgery in Canada. Read more: https://www.msn.com/en-ca/health/other/mobile-brain-scans-sound-like-science-fiction-but-they-re-now-helping-more-canadian-patients/ar-AA1YlZWc
PNA Highlights April 2026
“Remain calm, because peace equals power.” – Joyce Meyer
PNA Spotlight: Dr. Maria Peris Celda
This month the PNA Spotlight focuses on Dr. Maria Peris Celda, a Professor in Neurosurgery, Otolaryngology, and Surgical Anatomy at Mayo Clinic in Rochester, Minnesota. Dr. Peris Celda earned a PhD in neurosciences and her MD from the University of Valencia in Spain. She has done a fellowship in Microsurgical Endoscopic Anatomy at the University of Florida in Gainesville; and a Neurosurgical Skull Base Oncology fellowship at Mayo Clinic in Rochester, Minnesota. She also completed two residencies in neurological surgery: at the University of Valencia in Spain, and at Albany Medical Center in New York. She was kind enough to answer some questions from the PNA. Her answers follow.
Please tell us about your background.
I was born in Valencia, Spain and earned my undergraduate degree, PhD, and my medical degree there. I specialize in skull base surgery, and a great part of my practice includes treatment of pituitary adenomas.
Why did you choose pituitary medicine?
Treatment of these complex lesions (found around very delicate structures) is really challenging. It requires focus, care and attention. It’s extraordinary because each case is unique. I really enjoy performing surgeries that give the patient the best, safest standard of care.
Read More Here
Navigating Complex Pituitary Surgery Safely, Dr. Maria Peris Celda
Pituitary tumors often sit in one of the most delicate areas of the brain. While many can be treated safely and effectively, some grow into nearby spaces that make surgery more complex.
According to Mayo Clinic neurosurgeon Maria Peris Celda, MD, PhD one of the most challenging areas to operate is the cavernous sinus, a narrow corridor close to the pituitary gland. This anatomically complex region contains critical arteries and nerves responsible for eye movement and blood flow to the brain, which means even minor injuries can have profound consequences.
For years, tumors involving this area were often considered too risky to remove surgically. But advances in endoscopic surgery, performed through the nose without external incisions, have changed what’s possible. Despite this, success depends on a surgeon’s deep understanding of the anatomy hidden just millimeters from the pituitary gland.
That is the focus of Dr. Peris Celda’s recent research, which intricately maps the tiny blood vessels branching off the internal carotid artery as they pass through the cavernous sinus. These vessels are not usually visible on imaging but play a critical role in supplying blood to the nerves that control eye movement and sensation.
Using detailed anatomical specimen dissections performed from the same endoscopic viewpoint used in modern surgery, Dr. Peris Celda and her colleagues identified consistent landmarks that help surgeons navigate this area more safely.
In the past, surgeons had to open the skull and retract the brain to study and reach this region. Today, advanced endoscopic techniques allow surgeons to access the same anatomy through the nasal passages, offering a direct view without external incisions. Their work shows which blood vessels and branches of the internal carotid artery are present in every person, where they are located in relation to the pituitary gland, and which nerves they support.
Dr. Peris Celda notes that knowledge of these blood vessels and its variations help in avoiding injury to one of the main arteries that supply blood flow to the brain, the carotid artery. She also explains that nerve injuries do not always occur from direct damage to the nerve itself. In some cases, problems arise when blood flow to the nerve is disrupted. Understanding the location of these small vessels helps surgeons reduce that risk.
For pituitary tumor patients, this research translates directly into safer care. By understanding these anatomical details, surgeons can remove more tumor tissue while reducing the risk of complications such as carotid artery injury, double vision, eye movement problems, or stroke. It also allows experienced teams to operate in areas that were once avoided altogether.
At Mayo Clinic in Rochester, Minnesota, pituitary surgery is performed by a specialized team that includes neurosurgeons, ear, nose and throat surgeons, endocrinologists, and ophthalmologists. This multidisciplinary approach ensures that each patient’s tumor, hormone function, and vision are carefully evaluated before and after surgery.
For patients facing complex pituitary tumors, this exceptional expertise can make all the difference, offering safer surgery, better outcomes, and greater peace of mind.
For more information or to request an appointment, please visit Pituitary Tumors – Mayo Clinic.
PNA Medical Corner: X-Linked Acrogigantism
This month the PNA Medical Corner focuses on a study coauthored by longtime PNA member Albert Beckers. It looks at a severe form of pituitary gigantism called X-LAG.

Ann Endocrinol (Paris)
. 2026 Mar 24:102511.
doi: 10.1016/j.ando.2026.102511. Online ahead of print.
Genome architecture in endocrine diseases: X-Linked Acrogigantism (X-LAG) syndrome
Adrian F Daly 1, Albert Beckers 2, Patrick Pétrossians 2
Affiliations Expand
- PMID: 41887597 DOI: 10.1016/j.ando.2026.102511
Abstract
X-linked acrogigantism (X-LAG) is a rare disease that represents a severe form of pituitary gigantism characterized by early-onset growth hormone (GH), insulin-like growth factor 1 (IGF1) and prolactin excess. X-LAG is associated with duplications involving the gene GPR101 on chromosome Xq26.3. Clinically, X-LAG manifests in infancy, with a median age at onset of 18 months, presenting as rapid linear growth, acral enlargement, and large pituitary macroadenomas. While predominantly a sporadic disease affecting females through constitutional duplications, somatic mosaicism is found in sporadic male cases. Three familial cases of X-LAG have been described. Management is difficult due to the young age of affected patients and the relative resistance of GH excess to somatostatin analogs. Multimodal therapy, including neurosurgery and medical therapy such as pegvisomant, is often required to achieve hormonal control and limit final adult height. Unlike other genetic forms of pituitary tumorigenesis that are due to sequence-based mutations, X-LAG is caused by structural changes in 3D genome architecture. Specifically, microduplications on chromosome Xq26.3 disrupt a topologically associating domain (TAD) containing GPR101. This process facilitates the formation of a “neoTAD,” where the GPR101 promoter is driven by ectopic enhancers, primarily an intronic enhancer located within the VGLL1 gene, leading to massive pituitary upregulation of this constitutively active receptor and GH excess. X-LAG is an example of how novel disease mechanisms can explain the molecular dysregulation behind rare and difficult to manage endocrine pathologies.
Keywords: GPR101; TAD; X chromosome; X-linked acrogigantism; acromegaly; gigantism; topologically associated domain.
Copyright © 2026 Elsevier Masson SAS. All rights reserved.
Count on your Xeris CareConnection™ Team for unparalleled Cushing’s Support
Cushing’s can be challenging, but there is support so patients can feel like themselves again. The main goal of treating Cushing’s is to get cortisol levels back to normal. This Pituitary Awareness Month, Xeris Pharmaceuticals® is highlighting the importance of one-on-one support for patients living with Cushing’s Syndrome and support for HCPs treating Cushing’s Syndrome.
Sign up to get dedicated support:
Patients: Sign up for support | Recorlev® (levoketoconazole)
HCP’s: Connect with Xeris support | RECORLEV® (levoketoconazole)
Have more questions? Call for more support at 1-844-444-RCLV (7258)
Copyright © 2024 Pituitary Network Association All rights reserved.
Disclaimer: PNA does not engage in the practice of medicine. It is not a medical authority, nor does it claim to have medical expertise. In all cases, PNA recommends that you consult your own physician regarding any course of treatment or medication.
Our mailing address is:
Pituitary Network Association
P.O. Box 1958
Thousand Oaks, CA 91358
(805) 499-9973 Phone - (805) 480-0633 Fax
Email [email protected]
You are receiving this Newsletter because you have shown interest in receiving information about our activities.
If you do not want to receive any more emails from PNA, Unsubscribe.
Research Articles April 2026
Pituitary Tumors
Li J, Qu Y, Zhang W, Yang Z, Zeng Y, Xu J, Xie K, Liu Q.Int J Mol Med. 2026 Jun;57(6):151. doi: 10.3892/ijmm.2026.5822. Epub 2026 Apr 3.
Dzhatieva DN, Pigarova EA, Dzeranova LK.Zh Vopr Neirokhir Im N N Burdenko. 2026;90(2):98-102. doi: 10.17116/neiro20269002198.
[Impact of cabergoline on fibrosis in prolactinoma].
Matsueva IA, Paltsev AA, Guseva KA, Tsoy UA, Grineva EN.Zh Vopr Neirokhir Im N N Burdenko. 2026;90(2):85-91. doi: 10.17116/neiro20269002185.
Klochkova IS, Astafyeva LI, Kutin MA, Konovalov AN, Sidneva YG, Shkarubo AN, Kalinin PL.Zh Vopr Neirokhir Im N N Burdenko. 2026;90(2):77-84. doi: 10.17116/neiro20269002177.
Fedai NK, Uzun N, Bostan H, Kizilgul M, Demirci T, Cakal E, Ucan B.Hormones (Athens). 2026 Apr 2. doi: 10.1007/s42000-026-00766-3. Online ahead of print.
Lozouet M, Saadoun A, Ménard A, Aldea S, Jaoude SA, Heran F, Yavchitz A, Philibert M, Chauvet D.Clin Neurol Neurosurg. 2026 Mar 28;267:109409. doi: 10.1016/j.clineuro.2026.109409. Online ahead of print.
Hajikarimloo B, Mohammadzadeh I, Tos SM, Bahri A, Sabaghian A, Habibi MA.Endocrine. 2026 Apr 1;91(1):118. doi: 10.1007/s12020-026-04590-y.
Pituitary disorders
Recurrent pituitary apoplexy: experience from a national registry and review of the literature.
Biagetti B, Cordero Asanza E, Iglesias P, Camara R, Asla Q, Vicente A, Martinez-Saez E, Sarria-Estrada S, Puig-Domingo M, Araujo-Castro M.Ther Adv Endocrinol Metab. 2026 Mar 28;17:20420188261434641. doi: 10.1177/20420188261434641. eCollection 2026.
Post-Traumatic Pituitary Stalk Transection Syndrome.
Albusaidi R, AlHatmi A, Al Shidhani A, Al-Ajmi E.Sultan Qaboos Univ Med J. 2026 Mar 7;26(1):230-232. doi: 10.18295/2075-0528.2977. eCollection 2026.
Al-Shamkhi N, Edén Engström B, Rask E, Anderzén-Carlsson A.PLoS One. 2026 Mar 31;21(3):e0345909. doi: 10.1371/journal.pone.0345909. eCollection 2026.
Valeri F, Zoli M, Lillo S, Tengattini F, Colombo F, Pasquini E, Salierno G, Carretta A, D’Ambrosio L, Babaei D, Agosti E, Mattogno PP, Fontanella MM, Lauretti L, Mazzatenta D, Doglietto F, Iannalfi A.Neurosurg Rev. 2026 Mar 31;49(1):331. doi: 10.1007/s10143-026-04258-1.
Cushing’s
Chen B, He C, Han L, Wang H, Ma Y, Wang R, Cai X.Onco Targets Ther. 2026 Feb 6;19:571776. doi: 10.2147/OTT.S571776. eCollection 2026.
Jamal HF.JCEM Case Rep. 2026 Mar 31;4(4):luag039. doi: 10.1210/jcemcr/luag039. eCollection 2026 Apr.
Mangone A, Sala E, Carosi G, Sindaco GD, Mungari R, Cremaschi A, Petria I, Noschese G, Lotito V, Mantovani G, Ferrante E.Pituitary. 2026 Apr 1;29(2):68. doi: 10.1007/s11102-026-01668-8.
Rivera-Martínez WA, Ramírez Castaño MJ, Cruz Calderón S, Díaz Posada NA, Gutiérrez Restrepo J, Román-González A, Aristizábal Henao N, Castaño Ceballos PA, Tobón Ospina CI, Donado Gómez JH, López Pompey N, Builes-Montaño CE.Ther Adv Endocrinol Metab. 2026 Mar 28;17:20420188261434078. doi: 10.1177/20420188261434078. eCollection 2026.
Nitya AAV, Ghosh J, Taneja S, Singla V, Kalra N, Dutta P.Indian J Endocrinol Metab. 2026 Jan-Feb;30(1):79-84. doi: 10.4103/ijem.ijem_821_25. Epub 2026 Feb 27.
Quan W, Zhao DW, Li L, Chen HR, Wang L, Hu SL, Hu R.World Neurosurg. 2026 Mar 28:124958. doi: 10.1016/j.wneu.2026.124958. Online ahead of print.PMID: 41912140
Acromegaly
Meningoencephalitis and secondary pituitary abscess in a 16-year-old patient with gigantism.
Wissa M, Strenger V, Weinhandl G, Braun H, Wolfsberger S, Micko A.JCEM Case Rep. 2026 Apr 1;4(4):luag032. doi: 10.1210/jcemcr/luag032. eCollection 2026 Apr.
The silent surden: Alexithymia and quality of life in acromegaly patients.
Soltanova L, Aygun AB, Kocaman BB, Muradov I, Taze SS, Turan S, Kadioglu P, Durcan E.Endocrine. 2026 Apr 2;91(1):135. doi: 10.1007/s12020-026-04606-7.
To test or not to test: what we have learnt from 50 years of dynamic testing in acromegaly.
De Marinis L, Chiloiro S, Mancini A, Giambò P, Giampietro A, Bianchi A, Pontecorvi A, Giustina A.Pituitary. 2026 Mar 31;29(2):67. doi: 10.1007/s11102-026-01649-x.
Tsatsaris E, Robèrt J, Burman P, Berinder K, Bonelli L, Dahlqvist P, Höybye C, Ragnarsson O, Vouzouneraki K, Åkerman AK, Ekman B, Engström BE.J Clin Endocrinol Metab. 2026 Mar 30:dgag137. doi: 10.1210/clinem/dgag137. Online ahead of print.PMID: 41913644
Acromegaly-Physiopathology and etiology.
Castinetti F.Vitam Horm. 2026;131:83-102. doi: 10.1016/bs.vh.2026.01.001. Epub 2026 Jan 28.PMID: 41912301 Review.
Co-secreting pituitary adenomas in acromegaly: Classification, diagnosis, and treatment strategies.
Biagetti B, Araujo-Castro M.Vitam Horm. 2026;131:41-57. doi: 10.1016/bs.vh.2025.06.002. Epub 2025 Dec 3.
Acromegaly and histopathology.
Caballero GA, Ribalta T, Aldecoa I.Vitam Horm. 2026;131:293-334. doi: 10.1016/bs.vh.2025.10.007. Epub 2025 Nov 13.PMID: 41912298 Review.
New molecular markers of response to medical therapy in acromegaly.
Raventós A, Gil J, Marques-Pamies M, de Pedro-Campos P, Puente de la Vega C, Picó A, Lamas C, Delgado E, Menéndez E, Serra G, Bernabéu I, Villar R, Ferri J, Mariaca K, Martínez R, Marazuela M, Araujo-Castro M, Biagetti B, Jordà M, Valassi E, Puig-Domingo M; ACROMICS investigators.Vitam Horm. 2026;131:265-292. doi: 10.1016/bs.vh.2025.10.006. Epub 2025 Nov 12.
de Lapiscina IM, Baquero C, Castaño L.Vitam Horm. 2026;131:235-263. doi: 10.1016/bs.vh.2025.10.008. Epub 2025 Dec 16.PMID: 41912295 Review.
Donato S, Regala C, Marques P.Vitam Horm. 2026;131:195-234. doi: 10.1016/bs.vh.2025.10.005. Epub 2026 Feb 16.PMID: 41912294 Review.
Hormonal Health
Wu H, Jian MT, Ning G, Li BN, Peng AJ, Wang HY, Tang X, Zhou X.Asian J Androl. 2026 Apr 3. doi: 10.4103/aja2025105. Online ahead of print.
From the perspective of prolactin: a view on obesity.
Wang Y, Luo D, Fang G, Ge M, Huang Y, Deng H.Front Endocrinol (Lausanne). 2026 Mar 16;17:1762596. doi: 10.3389/fendo.2026.1762596. eCollection 2026.
Gonadotropins Across the Lifespan: Their role in the Neurodevelopment-Neurodegeneration Continuum.
Galbraith JA, Elhassan MZ, Rocha JF, Al Mozani TA, Fredericks CA.Yale J Biol Med. 2026 Mar 31;99(1):199-215. doi: 10.59249/EVST3084. eCollection 2026 Mar.
Dayno AN, Crowley J, Bamba V, Bhoj EJK, Shekdar K, McCormack SE.Neoreviews. 2026 Apr 1;27(4):e211-e221. doi: 10.1542/neo.27-4-002.
Unconventional Uses of Human Growth Hormone.
Lisbona-Buzali M, Edid-Jaris G, Alegre-Lifshitz A, Mercado-Medrez S, Taniguchi-Ponciano K, Marrero-Rodriguez D, Mercado M.Arch Med Res. 2026 Mar 30;57(5):103412. doi: 10.1016/j.arcmed.2026.103412. Online ahead of print.PMID: 41915988 Review.
Elia A.Arch Endocrinol Metab. 2026 Jun 1;70(3):e260025. doi: 10.20945/2359-4292-2026-0025.
TRH can stimulate the release of two POMC-derived pituitary hormones, ACTH and MSH, in medaka.
Yamakawa M, Gajbhiye DS, Golan M, Kanda S.Endocrinology. 2026 Mar 30:bqag037. doi: 10.1210/endocr/bqag037. Online ahead of print.
PNA Spotlight: Dr. Maria Peris Celda
PNA Spotlight: Dr. Maria Peris Celda
This month the PNA Spotlight focuses on Dr. Maria Peris Celda, a Professor in Neurosurgery, Otolaryngology, and Surgical Anatomy at Mayo Clinic in Rochester, Minnesota. Dr. Peris Celda earned a PhD in neurosciences and her MD from the University of Valencia in Spain. She has done a fellowship in Microsurgical Endoscopic Anatomy at the University of Florida in Gainesville; and a Neurosurgical Skull Base Oncology fellowship at Mayo Clinic in Rochester, Minnesota. She also completed two residencies in neurological surgery: at the University of Valencia in Spain, and at Albany Medical Center in New York. She was kind enough to answer some questions from the PNA. Her answers follow.
Please tell us about your background.
I was born in Valencia, Spain and earned my undergraduate degree, PhD, and my medical degree there. I specialize in skull base surgery, and a great part of my practice includes treatment of pituitary adenomas.
Why did you choose pituitary medicine?
Treatment of these complex lesions (found around very delicate structures) is really challenging. It requires focus, care and attention. It’s extraordinary because each case is unique. I really enjoy performing surgeries that give the patient the best, safest standard of care.
Who were your mentors?
I have to credit Dr. Albert Rhoton at the University of Florida. He passed away 10 years ago and was one of the most influential neurosurgeons of all time. He started as staff at Mayo Clinic and then went to the University of Florida for most of his career, where I did a two-year fellowship under his guidance. Dr. Rhoton focused on teaching better ways to perform surgery through research and anatomical dissections. It is my goal to continue this research in order to find new ways to approach tumors. Better anatomical knowledge will bring safer surgeries. I also learn every day from the team approach and expertise of my great colleagues at Mayo Clinic. It is a privilege to work with them.
Please tell me more about your research.
The goal of my research is to find safer, newer ways to approach pathologies and find optimal ways to train future generations. A surgeon must know what can go wrong and be able to anticipate and prevent problems. I came to Mayo Clinic many years ago to do a specialized clinical fellowship in skull base diseases. We see a great number of these types of surgery. I have gained valuable experience that allows me to remove tumors more safely, with better patient outcomes. My research is highly applicable to clinical care. We want to find essential anatomical details that can have direct consequences for patients. The more we know about the pathology and the way these delicate anatomical structures interact with each other, the better the result will be.
What would you like people to know about your practice?
The most important thing is that we treat our patients as we would our own family members. We talk to patients about their goals and find out what’s important to them. We give skillful, specialized and unique care to each patient, based on who they are as human beings and what they want to get out of treatment.
It is very important to have a well-rounded team of specialists focused on each patient. In this highly specialized field, practitioners really need to dedicate their lives to achieve the best results. That is true for neurosurgery as well as for ENT rhinologists, endocrinologists, radiologists, and radiation oncologists. When patients need pituitary surgery, they must feel good about the treatment team. The team at Mayo has the experience necessary to safely perform complex surgeries.
What do you see as the future of your field?
Neurosurgery is becoming increasingly technologically advanced. In the future, I’m sure that neurosurgeons will increasingly use robotics to safely advance the field. There’s no question in my mind that the skills that we develop are going to be aided by technology. This will deliver even better results. However, the most important part of surgery will always be the judgment to know how far to go for each particular patient. Surgeons must know what can lay hidden behind a structure, so it is not accidentally injured during the operation. That judgment is based on knowledge and experience, not technology. Technology is a great help, but it is not the main driver of surgical excellence.
What is the extent of your involvement with the Pituitary Network Association?
My collaboration with the PNA has been a very rewarding experience. Over the past few years, we put together seminars to raise patient awareness. We love having direct contact with patients. PNS helps us reach a larger audience of patients. I enjoyed explaining the anatomy, and showing how things work in surgery and post-operative care. The videos are available for everyone to watch on the website. So, it has been really great to be able to answer questions from patients and impart accurate information.
PNA Highlights October 2024
“Your body holds deep wisdom. Trust in it. Learn from it. Nourish it. Watch your life transform and be healthy.”
– Bella Bleue
PNA Spotlight: Dr. Yuval Eisenberg
This month the PNA Spotlight shines on Dr. Yuval Eisenberg. Dr. Eisenberg graduated from Rush Medical College at Rush University Medical Center in 2009. He works in Chicago, IL and two other locations and specializes in internal medicine as well as endocrinology, diabetes & metabolism. Dr. Eisenberg is also affiliated with the University of Illinois Hospital Health & Science Center. He was kind enough to answer some of our questions:
What inspired you to choose your career path?
My career path was guided by my interaction with patients and my mentors. The highlight of my medical school training was helping to diagnose a young man suffering from multiple endocrine neoplasia type 1 (MEN1), a rare genetic disorder causing multiple tumors, including a pituitary adenoma. Listening to his concerns and thinking outside the box, I helped provide him with the correct diagnosis and treatment plan – and started my journey into endocrinology. I have been fortunate to work with excellent clinician-educators in my career. Learning about and observing the care of patients with endocrine-related problems was fascinating and rewarding. The farther I got in my training, the more I realized that endocrinology was my passion and that patients with pituitary disorders would be my sub-focus. Patients with pituitary disease are a unique population who are in need of education, support and reassurance at diagnosis – and they often require long-term follow-up. This allows for time to develop a bond of trust; an aspect of medical practice I thoroughly enjoy.
Safeguarding the nose during pituitary tumor surgery
Pituitary tumors are typically removed through the nose during endoscopic transnasal transsphenoidal surgery. Although minimally invasive, that approach requires expertise to minimize surgical trauma to the nose. Fortunately, surgeons are using new techniques that help safeguard the nose and maximize patients’ quality of life after surgery.
“The tendency now is to be less invasive in the approach through the nose,” explains Dr. Carlos D. Pinheiro Neto, a Mayo Clinic ENT/head and neck surgeon. “A very aggressive approach can cause chronic nasal crusting and infections, scabbing, decreased sense of smell and taste, and changes in the nose’s appearance.”
In endoscopic transnasal transsphenoidal surgery, a small surgical camera and surgical instruments are placed through the nostrils to access the tumor through the sinuses. Mayo Clinic was among the first institutions to extensively research the approach. As initially developed, the procedure involved extensive nasal resection.
“The idea was to create a maximum opening of the sinuses to allow neurosurgeons to reach and remove the tumor from the skull base,” Dr. Pinheiro Neto says. “The nasal physiology and sinus symptoms after the surgery were not a priority — the nose was just a corridor to the tumor.”
Now, Dr. Pinheiro Neto is pioneering surgical techniques that minimize resection of the nasal and sinus structures. One involves leaving intact the middle turbinate, which plays important roles in nasal airflow, warming and filtering air to the lungs, and smelling. Another is using a nasal-floor graft to provide a seal between the nose and brain after tumor removal. The standard procedure when cerebrospinal fluid leaks during surgery involves a nasal septal flap created from the septum — the tissue that separates the nostrils’ two airways.
“Nasal graft is much better for patients. It avoids the exposure of the nasal septum cartilage, so there is less crusting and faster healing,” Dr. Pinheiro-Neto says. “Nasal septal flaps can also cause a structural collapse in the nasal bridge and increase the risk of septal perforations. Since changing our paradigm from nasal septal flap for pituitary surgery, our leak rate is 0.1%.”
The new techniques are based on research conducted in Mayo Clinic’s anatomy laboratory. Those lessons are translated to the operating room, where ENT/head and neck surgeons routinely work alongside neurosurgeons to remove pituitary tumors.
“That research has allowed us to achieve the same level of tumor resection and treatment outcomes, but with fewer complications,” Dr. Pinheiro-Nato says. “With time and experience, we have realized it’s possible to preserve most of the nose and still get good space in the back of the sinus for tumor removal.
“This is about improving patients’ quality of life,” Dr. Pinheiro-Neto says. “They can have a nasal procedure but after a few weeks of healing, the nose and nasal physiology, and the sinuses, are as good as ever before.”
Stanford Hosts Pituitary Patient Education Day
Stanford University invites the public to their free pituitary patient education day, to be held both in-person and via zoom on Saturday November 9th, 2024. The event will run from 8am-5pm and will take place in the Assembly Hall at Stanford Hospital.
The course co-directors include neurosurgeon Juan C. Fernandez-Miranda, MD (a longtime member of the PNA), and endocrinologist Julia Chang, MD. Topics to be discussed include the function of the pituitary gland, endonasal endoscopic surgery, cavernous sinus surgery, radiotherapy, Cushing’s, acromegaly, prolactinoma and more.
Count on your Xeris CareConnection™ Team for unparalleled Cushing’s Support
Cushing’s can be challenging, but there is support so patients can feel like themselves again. The main goal of treating Cushing’s is to get cortisol levels back to normal. This Pituitary Awareness Month, Xeris Pharmaceuticals® is highlighting the importance of one-on-one support for patients living with Cushing’s Syndrome and support for HCPs treating Cushing’s Syndrome.
Sign up to get dedicated support:
Patients: Sign up for support | Recorlev® (levoketoconazole)
HCP’s: Connect with Xeris support | RECORLEV® (levoketoconazole)
Have more questions? Call for more support at 1-844-444-RCLV (7258)
Copyright © 2024 Pituitary Network Association All rights reserved.
Disclaimer: PNA does not engage in the practice of medicine. It is not a medical authority, nor does it claim to have medical expertise. In all cases, PNA recommends that you consult your own physician regarding any course of treatment or medication.
Our mailing address is:
Pituitary Network Association
P.O. Box 1958
Thousand Oaks, CA 91358
(805) 499-9973 Phone - (805) 480-0633 Fax
Email [email protected]
You are receiving this Newsletter because you have shown interest in receiving information about our activities.
If you do not want to receive any more emails from PNA, Unsubscribe.
News Articles October 2024
New acromegaly drug on the horizon
A new drug for treatment and long-term maintenance therapy for acromegaly is now on the horizon. Crinetics Pharmaceuticals recently submitted its first new drug application (NDA) to the U.S. Food and Drug Administration for paltusotine, which is a once-daily oral selectively-targeted somatostatin receptor type 2 nonpeptide agonist.
Crinetics says researchers used data from from 18 clinical trials in the application, including two Phase 3 trials that evaluated paltusotine for acromegaly in medically untreated and treated patients. Patients tolerated the treatment well, the medication achieved biochemical control by maintaining IGF-1 levels and improved patients’ symptoms compared to placebo. The company says it expects to hear back from the FDA by December.
Paltusotine, is the first drug of its type to complete Phase 3 clinical development for acromegaly and is now in Phase 2 clinical development for carcinoid syndrome associated with neuroendocrine tumors. Read the company’s press release here.
Can machine learning to predict hormone deficiency after pituitary surgery?
A study featured on Nature.com used machine learning algorithms to predict whether patients would develop arginine vasopressin deficiency after transsphenoidal surgery to remove a pituitary adenoma. Read more here: https://www.nature.com/articles/s41598-024-72486-w
Pituitary apoplexy strikes groom on wedding day
An article in People.com tells the story of a groom in England who had to leave his wedding reception early due to a severe headache – one that turned out to be a hemorrhaging pituitary tumor. Read more here: https://people.com/groom-migraine-wedding-day-tumor-popped-8718083
Researchers try to make synthetic oxytocin for pain relief
An article in the Focus.news looks at efforts to replicate the hormone oxytocin in the lab – in an effort to develop a painkiller that would be safer than opioids. Read more here: https://www.thefocus.news/lifestyle/scientists-are-hoping-to-replicate-the-cuddle-hormone-for-healthy-long-term-pain-relief/
PNA Spotlight: Dr. Leena Shahla

This month the PNA Spotlight focuses on endocrinologist Dr. Leena Shahla, director of the Duke Pituitary Center, part of Duke Health in Durham, North Carolina. The program is listed by the PNA as a center of pituitary excellence. Dr. Shahla graduated medical school at Al-Baath University (in Homs, Syria), did her residency in internal medicine at St. Joseph’s at New York Medical College, and completed a fellowship in endocrinology at the University of Massachusetts Medical School. Her pituitary focus has grown significantly over the years. She initiated the pituitary tumor board at the University of Florida, Jacksonville, and later built the pituitary clinic at the University of Arizona, Phoenix. She arrived at Duke this past July. Dr. Shahla was kind enough to answer a few questions from the PNA. Below is the conversation.
Please tell us about your work at Duke.
At Duke, I am the neuroendocrinologist and medical director of Duke Pituitary Center. Our multidisciplinary team includes specialists in neurosurgery, neuro-ophthalmology, ENTs, neuro-oncology, and neuro-radiology. We run a multi-disciplinary clinic. When patients visit for evaluation, they often start with visual field testing, followed by appointments with me and one of the neurosurgeons, all in one place. We all collaborate closely behind the scenes to make the best plan for each patient.
What inspired you to choose this career path?
My interest in hormones and their role in regulating various physiological systems led me to specialize in endocrinology. And then, as I realized the significant impact of the pituitary on the endocrine system, I found the challenge of diagnosing and treating pituitary conditions fascinating, much like solving a complex puzzle. So ultimately, that inspired me to specialize in pituitary disorders.
What is the primary focus of your work or research?
We’re working on a study on the link between hypogonadism and prolactinoma. We are also going to be looking into early diagnosis of Cushing’s and acromegaly.
How has endocrinology evolved since you got into it, and where do you think it’s going?
Medicine today is more advanced than ever. Especially in my specialty, there have been advancements in pituitary-focused diagnostic tests and new treatments continue to emerge. This progress is especially beneficial for complex cases that previously had limited treatment options. The field is moving forward with studies and clinical trials underway. Cushing’s and acromegaly are rare diseases and often leave patients suffering for years before diagnosis. However, with greater public awareness and improved testing, patients are being diagnosed earlier.
What should patients know about endocrinology? What needs more awareness?
Cushing’s Syndrome and acromegaly deserve more awareness, as many patients go undiagnosed for long periods. Not all cases present with obvious symptoms making it crucial for primary care physicians and other providers to recognize early signs. When patients are diagnosed in advanced stages, treatment becomes more challenging. Raising awareness can guide physicians to screen for Cushing’s syndrome and acromegaly or refer patients to endocrinology. This proactive approach can help us identify, diagnose, and treat patients sooner.
What are some of the signs that doctors and patients should be looking for, for acromegaly and Cushing’s?
Both patients and providers should be aware of certain signs and symptoms, although they can be subtle or develop gradually.
For Cushing’s, signs could be unexplained weight gain, easy bruising, muscle weakness, mood changes (anxiety, depression, irritability), uncontrolled diabetes, or hypertension.
For acromegaly, some of signs are facial changes, hand and feet growth (increased ring or shoe size), joint pain and swelling, tingling in hands, jaw changes or pain, and widening of spaces between the teeth.
Early detection of these signs combined with diagnostic tests can help lead to timely intervention and management
What would you like to convey about yourself to your patients?
I believe that the doctor-patient relationship is built on communication, empathy, and trust. I am thorough in my approach, and when I meet patients, especially for the first time, I prioritize listening to their concerns, making sure I answer their questions and explain their conditions clearly so they understand. And I involve them actively in the decision-making process.
Empathy is essential, especially during the diagnosis and early stages of treatment before patients start feeling better. They need support, hand-holding, and understanding because they are often struggling physically, mentally, and emotionally. It is important to listen to their concerns patiently and guide them without getting frustrated. While we may not be able to cure everything, we can keep the disease very well-controlled, allowing them to feel better and supported.
What made you want to get involved with the PNA?
I always wanted to be involved with the PNA because pituitary disorders are not that common, and this group provides invaluable support to patients. My goal is to contribute as much as possible to help patients and community providers recognize the disease early. Patients must be referred to centers with the right resources for diagnosis and treatment. At the end of the day, we all care deeply about our patients’ well-being.
PNA Highlights October 2024
“Your body holds deep wisdom. Trust in it. Learn from it. Nourish it. Watch your life transform and be healthy.”
– Bella Bleue
PNA Spotlight: Dr. Yuval Eisenberg
This month the PNA Spotlight shines on Dr. Yuval Eisenberg. Dr. Eisenberg graduated from Rush Medical College at Rush University Medical Center in 2009. He works in Chicago, IL and two other locations and specializes in internal medicine as well as endocrinology, diabetes & metabolism. Dr. Eisenberg is also affiliated with the University of Illinois Hospital Health & Science Center. He was kind enough to answer some of our questions:
What inspired you to choose your career path?
My career path was guided by my interaction with patients and my mentors. The highlight of my medical school training was helping to diagnose a young man suffering from multiple endocrine neoplasia type 1 (MEN1), a rare genetic disorder causing multiple tumors, including a pituitary adenoma. Listening to his concerns and thinking outside the box, I helped provide him with the correct diagnosis and treatment plan – and started my journey into endocrinology. I have been fortunate to work with excellent clinician-educators in my career. Learning about and observing the care of patients with endocrine-related problems was fascinating and rewarding. The farther I got in my training, the more I realized that endocrinology was my passion and that patients with pituitary disorders would be my sub-focus. Patients with pituitary disease are a unique population who are in need of education, support and reassurance at diagnosis – and they often require long-term follow-up. This allows for time to develop a bond of trust; an aspect of medical practice I thoroughly enjoy.
Safeguarding the nose during pituitary tumor surgery
Pituitary tumors are typically removed through the nose during endoscopic transnasal transsphenoidal surgery. Although minimally invasive, that approach requires expertise to minimize surgical trauma to the nose. Fortunately, surgeons are using new techniques that help safeguard the nose and maximize patients’ quality of life after surgery.
“The tendency now is to be less invasive in the approach through the nose,” explains Dr. Carlos D. Pinheiro Neto, a Mayo Clinic ENT/head and neck surgeon. “A very aggressive approach can cause chronic nasal crusting and infections, scabbing, decreased sense of smell and taste, and changes in the nose’s appearance.”
In endoscopic transnasal transsphenoidal surgery, a small surgical camera and surgical instruments are placed through the nostrils to access the tumor through the sinuses. Mayo Clinic was among the first institutions to extensively research the approach. As initially developed, the procedure involved extensive nasal resection.
“The idea was to create a maximum opening of the sinuses to allow neurosurgeons to reach and remove the tumor from the skull base,” Dr. Pinheiro Neto says. “The nasal physiology and sinus symptoms after the surgery were not a priority — the nose was just a corridor to the tumor.”
Now, Dr. Pinheiro Neto is pioneering surgical techniques that minimize resection of the nasal and sinus structures. One involves leaving intact the middle turbinate, which plays important roles in nasal airflow, warming and filtering air to the lungs, and smelling. Another is using a nasal-floor graft to provide a seal between the nose and brain after tumor removal. The standard procedure when cerebrospinal fluid leaks during surgery involves a nasal septal flap created from the septum — the tissue that separates the nostrils’ two airways.
“Nasal graft is much better for patients. It avoids the exposure of the nasal septum cartilage, so there is less crusting and faster healing,” Dr. Pinheiro-Neto says. “Nasal septal flaps can also cause a structural collapse in the nasal bridge and increase the risk of septal perforations. Since changing our paradigm from nasal septal flap for pituitary surgery, our leak rate is 0.1%.”
The new techniques are based on research conducted in Mayo Clinic’s anatomy laboratory. Those lessons are translated to the operating room, where ENT/head and neck surgeons routinely work alongside neurosurgeons to remove pituitary tumors.
“That research has allowed us to achieve the same level of tumor resection and treatment outcomes, but with fewer complications,” Dr. Pinheiro-Nato says. “With time and experience, we have realized it’s possible to preserve most of the nose and still get good space in the back of the sinus for tumor removal.
“This is about improving patients’ quality of life,” Dr. Pinheiro-Neto says. “They can have a nasal procedure but after a few weeks of healing, the nose and nasal physiology, and the sinuses, are as good as ever before.”
Stanford Hosts Pituitary Patient Education Day
Stanford University invites the public to their free pituitary patient education day, to be held both in-person and via zoom on Saturday November 9th, 2024. The event will run from 8am-5pm and will take place in the Assembly Hall at Stanford Hospital.
The course co-directors include neurosurgeon Juan C. Fernandez-Miranda, MD (a longtime member of the PNA), and endocrinologist Julia Chang, MD. Topics to be discussed include the function of the pituitary gland, endonasal endoscopic surgery, cavernous sinus surgery, radiotherapy, Cushing’s, acromegaly, prolactinoma and more.
Count on your Xeris CareConnection™ Team for unparalleled Cushing’s Support
Cushing’s can be challenging, but there is support so patients can feel like themselves again. The main goal of treating Cushing’s is to get cortisol levels back to normal. This Pituitary Awareness Month, Xeris Pharmaceuticals® is highlighting the importance of one-on-one support for patients living with Cushing’s Syndrome and support for HCPs treating Cushing’s Syndrome.
Sign up to get dedicated support:
Patients: Sign up for support | Recorlev® (levoketoconazole)
HCP’s: Connect with Xeris support | RECORLEV® (levoketoconazole)
Have more questions? Call for more support at 1-844-444-RCLV (7258)
Copyright © 2024 Pituitary Network Association All rights reserved.
Disclaimer: PNA does not engage in the practice of medicine. It is not a medical authority, nor does it claim to have medical expertise. In all cases, PNA recommends that you consult your own physician regarding any course of treatment or medication.
Our mailing address is:
Pituitary Network Association
P.O. Box 1958
Thousand Oaks, CA 91358
(805) 499-9973 Phone - (805) 480-0633 Fax
Email [email protected]
You are receiving this Newsletter because you have shown interest in receiving information about our activities.
If you do not want to receive any more emails from PNA, Unsubscribe.
October 2024 Research Articles
Pituitary Tumors
Duru M, Demir AN, Oz A, Kargin OA, Altunc AT, Demirel O, Arslan S, Kizilkilic O, Poyraz BC, Kadioglu P.J Endocrinol Invest. 2024 Oct 3. doi: 10.1007/s40618-024-02442-y. Online ahead of print.
Xu L, Lei Z, Wang Q, Jiang Q, Xing B, Li X, Guo X, Wang Z, Li S, Huang Y, Lei T.Antioxid Redox Signal. 2024 Oct 3. doi: 10.1089/ars.2024.0611. Online ahead of print.
Beyond Epistaxis: A Rare Case of Ectopic Sinonasal Adamantinomatous Craniopharyngioma.
Selva Kumaran K, Shamsudin NS, Dalip Singh HS, Devesahayam PR.Cureus. 2024 Sep 1;16(9):e68357. doi: 10.7759/cureus.68357. eCollection 2024 Sep.
Posterior pituitary tumors and other rare entities involving the pituitary gland.
Roncaroli F, Giannini C.Brain Pathol. 2024 Sep 30:e13307. doi: 10.1111/bpa.13307. Online ahead of print.PMID: 39350562 Review.
Pituitary Apoplexy in Pregnancy: Neonatal Implications.
Megan Y, Melissa S.Neoreviews. 2024 Oct 1;25(10):e660-e663. doi: 10.1542/neo.25-10-e660.
Zaher M, Kolmetzky DW, Al-Atrache Z, Vimawala S, Kolia NR, Godil SS.J Neurosurg Case Lessons. 2024 Sep 30;8(14):CASE24326. doi: 10.3171/CASE24326. Print 2024 Sep 30.
Zhang L, Yan S, Xie SK, Wei YT, Liu HP, Li Y, Wu HB, Wang HL, Xu PF.Endocr Connect. 2024 Sep 1:EC-24-0378. doi: 10.1530/EC-24-0378. Online ahead of print.
Acromegaly
Aliyeva T, Muniz J, Soares GM, Firdausa S, Mirza L.Pituitary. 2024 Oct 1. doi: 10.1007/s11102-024-01461-5. Online ahead of print.
Cushing’s
Braun LT, Vogel F, Nowak E, Rubinstein G, Zopp S, Ritzel K, Beuschlein F, Reincke M.Eur J Endocrinol. 2024 Oct 1:lvae127. doi: 10.1093/ejendo/lvae127. Online ahead of print.
Pituitary Surgery
De Nigris Vasconcellos F, Vilela MAD, Torrico FG, Scalise MA, Vargas VPS, Mendieta CD, Pichardo-Rojas P, Rosi MEA, Fleury LT, de Brito Rebelo ND, Benjamin C, Sheehan JP.Acta Neurochir (Wien). 2024 Oct 2;166(1):392. doi: 10.1007/s00701-024-06296-4.PMID: 39356336 Review.
Editor’s note: Dr. Sheehan is a member of the PNA.
Hormonal Health
Shimon I.Rev Endocr Metab Disord. 2024 Oct 2. doi: 10.1007/s11154-024-09902-z. Online ahead of print.PMID: 39356415 Review.
Saadeh NA, Obeidat M, Shboul M.Appl Clin Genet. 2024 Sep 26;17:143-149. doi: 10.2147/TACG.S466919. eCollection 2024.
Available Now!
The Pituitary Patient Resource Guide Sixth Edition is now available! Be one of the first to have the most up-to-date information. The Pituitary Patient Resource Guide a one of a kind publication intended as an invaluable source of information not only for patients but also their families, physicians, and all health care providers. It contains information on symptoms, proper testing, how to get a diagnosis, and the treatment options that are available. It also includes Pituitary Network Association's patient resource listings for expert medical care.

Xeris Pharmaceuticals is valued member of the PNA












